Mostrar el registro sencillo del ítem
Factores pronósticos y su impacto en los resultados clínicos en pacientes con leucemia mieloide aguda
dc.contributor.advisor | Sossa Melo, Claudia Lucía | |
dc.contributor.advisor | Ochoa Vera, Miguel Enrique | |
dc.contributor.author | Ortiz Tarazona, Selena María Fernanda | |
dc.coverage.spatial | Colombia | spa |
dc.date.accessioned | 2021-11-24T20:58:53Z | |
dc.date.available | 2021-11-24T20:58:53Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/15040 | |
dc.description.abstract | Introducción: La leucemia mieloide aguda (LMA) es la leucemia aguda más común en adultos, con una sobrevida global a 5 años de 27.7%, sin embargo comparado con periodos anteriores esta ha mejorado gracias a una mejor comprensión de los distintos factores pronósticos que incluyen los relacionados al paciente y a la enfermedad, pero suimpacto sobre los resultados clínicos de los pacientes con LMA de la clínica FOSCAL no se conocen. Objetivo: Identificar factores de asociación pronósticos respecto a la supervivencia global y supervivencia libre de eventos, en la cohorte de pacientes con leucemia mieloide aguda de la clínica FOSCAL, en el periodo comprendido entre el 01 de enero de 2009 al 30 de junio de 2021. Materiales y métodos: se registró retrospectivamente información sociodemográfica y de características clínicas de los pacientes con LMA atendidos en la FOSCAL. Se describen las características de los pacientes al diagnóstico; Análisis Kaplan Meier fue usado para evaluar la sobrevida global y sobrevida libre de eventos. Tambien se realizo calculo de hazzard ratio e intervalos de confianza del 95% crudos y ajustados por covariables. | spa |
dc.description.tableofcontents | Planteamiento Del Problema Y Justificación ......................................................................................... 8 Marco Teórico Y Estado Del Arte ......................................................................................................... 12 Leucemia Mieloide Aguda ........................................................................................................................... 12 Diagnóstico Y Clasificación .......................................................................................................................... 15 Morfológico ......................................................................................................................... 15 Inmunofenotipo .................................................................................................................. 16 Citogenética ........................................................................................................................ 16 Biología Molecular .............................................................................................................. 16 Clasificación ......................................................................................................................... 17 Estratificación Y Factores Pronósticos ..................................................................................................... 19 Factores Pronósticos Pretratemiento ................................................................................. 20 Factores Post-Tratamiento .................................................................................................. 22 Tratamiento ..................................................................................................................................................... 23 Tratamiento De Inducción .................................................................................................. 23 Tratamiento Post Remisión ................................................................................................. 24 Pregunta De Investigación ................................................................................................................... 25 Hipótesis ........................................................................................................................................................... 25 Objetivos .............................................................................................................................................. 26 Objetivo General ............................................................................................................................................ 26 Objetivos Específicos ..................................................................................................................................... 26 Metodología ........................................................................................................................................ 27 Tipo De Estudio ............................................................................................................................................... 27 Población .......................................................................................................................................................... 27 Criterios De Inclusión Y Exclusión .............................................................................................................. 27 Cálculo De Tamaño Muestral ..................................................................................................................... 27 Recolección De Información ....................................................................................................................... 28 Variables ........................................................................................................................................................... 28 Plan De Procesamiento Y Análisis De Datos ........................................................................................... 28 Consideraciones Éticas ................................................................................................................................. 29 Discusión .............................................................................................................................................. 54 Conclusiones ........................................................................................................................................ 63 Referencias Bibliográficas .................................................................................................................... 65 Anexos ......................................................................................... | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | * |
dc.title | Factores pronósticos y su impacto en los resultados clínicos en pacientes con leucemia mieloide aguda | spa |
dc.title.translated | Prognostic factors and their impact on clinical outcomes in patients with acute myeloid leukemia | spa |
dc.degree.name | Especialista en Medicina Interna | spa |
dc.publisher.grantor | Universidad Autónoma de Bucaramanga UNAB | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.publisher.faculty | Facultad Ciencias de la Salud | spa |
dc.publisher.program | Especialización en Medicina Interna | spa |
dc.description.degreelevel | Especialización | spa |
dc.type.driver | info:eu-repo/semantics/masterThesis | |
dc.type.local | Tesis | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | |
dc.subject.keywords | Internal medicine | spa |
dc.subject.keywords | Medicine | spa |
dc.subject.keywords | Medical sciences | spa |
dc.subject.keywords | Health sciences | spa |
dc.subject.keywords | Leukemias | spa |
dc.subject.keywords | Neoplasia | spa |
dc.subject.keywords | Precancerous conditions | spa |
dc.subject.keywords | Measurable residual disease | spa |
dc.subject.keywords | AML | spa |
dc.subject.keywords | Genetic abnormalities | spa |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga - UNAB | spa |
dc.identifier.reponame | reponame:Repositorio Institucional UNAB | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | 1. The Global Cancer Observatory - All Rights Reserved - May, 2019. | spa |
dc.relation.references | 2. Kolitz, JE. (2017) Overview of acute myeloid leukemia in adults. En Larson, RA (Ed), uptodate, 2020. | spa |
dc.relation.references | 3. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. Doi:10.1016/j.blre.2019.04.005 | spa |
dc.relation.references | 4. Siegel, Rebeca et al, cancer statistics 2020, CA CANCER J CLIN 2020;70:7–3, .doi: 10.3322/caac.21590. Available online at cacancerjournal.com | spa |
dc.relation.references | 5. Situación de cáncer en la población adulta atendida en el SGSSS de Colombia 2019, Cuenta de Alto Costo. Fondo Colombia de Enfermedades de alto costo (2019) | spa |
dc.relation.references | 6. Short, NJ, Rytting, ME y Cortes, JE (2018). Leucemia mieloide aguda. The Lancet, 392 (10147), 593–606. Doi: 10.1016 / s0140-6736 (18) 31041-9 | spa |
dc.relation.references | 7. Schuurhuis, G. J., Heuser, M, Freeman, S., Béné, M.-C, et al (2018). Minimal/measurable residual disease in AML: a consensus document from the European leukemianet MRD Working Party. Blood, 131(12), 1275–1291. Doi:10.1182/blood-2017-09-801498 | spa |
dc.relation.references | 8. Consenso basado en la evidencia: Indicadores de gestión del riesgo en adultos con leucemia linfoide aguda y leucemia mieloide aguda en Colombia, Fondo Colombiano de Enfermedades de Alto Costo, marzo de 2018 | spa |
dc.relation.references | 9. OECD Reviews of Health Systems: Colombia 2016 [En línea]. OECD Publishing; 2015 [cited 2017 Jul 13]. (OECD Reviews of Health Systems). Disponible en: http:// www.oecd ilibrary.org/social-issues-migration-health/oecd-reviews-of-health- systems-colombia 2015_9789264248908-en | spa |
dc.relation.references | 10. Valencia O, Lopes G, Sánchez P, Acuña L, Uribe D, González J. Incidence and Prevalence of Cancer in Colombia: The Methodology Used Matters. J Glob On- col [En línea]. 2017 Jul 6 [cited 2017 Jul 10];JGO.17.00008. Disponible en: http:// ascopubs.org/doi/10.1200/JGO.17.00008 | spa |
dc.relation.references | 11. Ministerio de Salud y Protección Social - Instituto Nacional de Cancerología E. Plan Decenal para el control del cáncer Colombia, 2012-2021 [En línea]. Bogotá D.C.: Ministerio de Salud y Protección Social. MSPS; 2012 [cited 2016 Aug 23]. 124 p. Disponible en: http://www.iccp-portal.org/sites/default/ les/plans/Plan- Decenal_controlcancer_2012 2021.pdf | spa |
dc.relation.references | 12. CONTROL DEL CÁNCER, ACCESO Y DESIGUALDAD EN AMÉRICA LATINA Una historia de luces y sombras. [cited 2017 Jul 13]; Disponible en: https://www. Eiuperspectives.economist.com/sites/default/ les/images/Cancer_control_ac- cess_and_inequality_in_Latin_America_SPANISH.pdf | spa |
dc.relation.references | 13. Rubnitz Jeffrey et al, acute myeloid leukemia, Hematology/Oncology Clinics of North America, 2010-02-01, Volumen 24, Número 1, Páginas 35-63 | spa |
dc.relation.references | 14. Howladern,nooneam,krapchom,millerd,bresta,yum,ruhlj,tatalovichz, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer sta- tistics review, 1975–2016. Bethesda, MD: National Cancer Institute; 2019https:// seer.cancer.gov/csr/1975_2016/ [based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Accessed 4/18/2019]. | spa |
dc.relation.references | 15. Gibson CJ, Steensma DP. Nuevas ideas de estudios de hematopoyesis clonal. Clin Cancer Res. 2018; 24 : 4633-4642 | spa |
dc.relation.references | 16. Lacher MJ, Sussman LN. Leukemia and Hodgkin's disease. Ann Intern Med 1963;59:369– 78. | spa |
dc.relation.references | 17. Reimer RR, Hoover R, Fraumeni Jr. JF, Young RC. Acute leukemia after alkylating- agent therapy of ovarian cancer. N Engl J Med 1977;297:177–81 | spa |
dc.relation.references | 18. Schonfeld SJ, Gilbert ES, Dores GM, Lynch CF, Hodgson DC, Hall P., et. Al .: Leucemia mieloide aguda después del linfoma de Hodgkin: un estudio poblacional de 35,511 pacientes. J Natl Cancer Inst 2006; 98: págs. 215-218 | spa |
dc.relation.references | 19. Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-macgregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant che- motherapy: a population based study among older breast cancer patients. Cancer 2018;124:899–906. | spa |
dc.relation.references | 20. Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, et al. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: a population-based study. Plos One 2017;12:e0184747 | spa |
dc.relation.references | 21. International Agency for Research on Cancer (IARC). Monographs on the eva- luation of the carcinogenic risk of chemicals to humans: Chemical agents and related occupations. Vol. 120. 2018. | spa |
dc.relation.references | 22. Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR. The health watch case-control study of leukemia and benzene: the story so far. Ann N Y Acad Sci 2006;1076:1080–9. | spa |
dc.relation.references | 23. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88(4):318-327. Doi:10.1002/ajh.23404). | spa |
dc.relation.references | 24. Terry PD, Shore DL, Rauscher GH, Sandler DP. Occupation, hobbies, and acute leukemia in adults. Leuk Res 2005;29:1117–30 | spa |
dc.relation.references | 25. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165–9. ) | spa |
dc.relation.references | 26. Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: a meta analysis. Sci Rep 2017;7:17998 | spa |
dc.relation.references | 27. Reyner J, et al, Leucemias agudas, Farreras rozman, medicina interna,209. 1643-1659, mayo 2020. | spa |
dc.relation.references | 28. Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T. Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424-447. Doi:10.1182/blood-2016-08 733196 | spa |
dc.relation.references | 29. Arber DA. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. Semin Hematol. 2019;56(2):90-95. Doi:10.1053/j.seminhematol.2018.08.002 | spa |
dc.relation.references | 30. Delgadillo O, et al, Caracterización de los pacientes con Leucemia mieloide aguda FOSCAL, 2019. | spa |
dc.relation.references | 31. Sanz MA, Iacoboni G, Montesinos P, Venditti A. Emerging strategies for the treatment of older patients with acute myeloid leukemia. Ann Hematol. 2016;95(10):1583-1593. Doi:10.1007/s00277-016-2666 | spa |
dc.relation.references | 30. Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population based registry study (AMLSG bio). Ann Hematol. 2017;96(12):1993-2003. Doi:10.1007/s00277-017-3150-3 | spa |
dc.relation.references | 33. Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88(8):642-646. Doi:10.1002/ajh.23462 | spa |
dc.relation.references | 34. Lancet, Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889-3897. Doi:10.1200/JCO.2012.45.9628 | spa |
dc.relation.references | 35. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377: 454–64 | spa |
dc.relation.references | 36. Tratamiento de la Leucemia Promielocítica Aguda de Nuevo Diagnóstico, protocolo PETHEMA LPA 2017 | spa |
dc.relation.references | 37. Ardila M, et al, alteraciones metabólicas post-trasplante de progenitores hematopoyéticos en la foscal de 2009 al 2017. 2019 | spa |
dc.relation.references | 38. Appelbaum FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol. 2013;26(3):279-284. Doi:10.1016/j.beha.2013.10.008 | spa |
dc.relation.references | 39 aribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021 Jun;100(6):1359-1376. doi: 10.1007/s00277-020-04375-x. | spa |
dc.relation.references | 40 Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481-5. doi: 10.1182/blood-2005-09-3724. Epub 2006 | spa |
dc.relation.references | 41. Jung J, Cho B, Kim H, Han E, Jang W, Han K, Lee J, Chung N, Cho B, Kim M, Kim Y. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification. Ann Lab Med 2019;39:311-316 https://doi.org/10.3343/alm.2019.39.3.311 | spa |
dc.relation.references | 42 Ana María Amor Vigil, La biología molecular en el diagnóstico de la leucemia mieloide aguda, Revista Cubana de Hematología, Inmunología y Hemoterapia. 2019; 35 (3): a_987, https://orcid.org/0000-0001-9182-2 | spa |
dc.relation.references | 43 mith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 1;102(1):43-52. doi: 10.1182/blood-2002-11-3343. Epub 2003 Mar 6. PMID: 12623843 | spa |
dc.relation.references | 44 Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G, Stockelberg D, Lehmann S. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015 Mar;90(3):208-14. doi: 10.1002/ajh.23908. Epub 2015 Jan 16. PMID: 25421221. | spa |
dc.relation.references | 45 Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015 Nov 1;33(31):3641-9. doi: 10.1200/JCO.2014.60.0890. Epub 2015 Aug 24. PMID: 26304885 | spa |
dc.relation.references | 46 Finn L, Sproat L, Heckman MG, Jiang L, Diehl NN, Ketterling R, Tibes R, Valdez R, Foran J. Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiol. 2015 Dec;39(6):1084-92. doi: 10.1016/j.canep.2015.09.003. Epub 2015 Sep 11. PMID: 26365691. | spa |
dc.relation.references | 47 M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska, C. Buske, on behalf of the ESMO Guidelines Committee | spa |
dc.relation.references | 48 M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska, C. Buske, on behalf of the ESMO Guidelines Committee | spa |
dc.relation.references | 49 amamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb;110:20-34. doi: 10.1016/j.critrevonc.2016.12.004. Epub 2016 Dec 11. PMID: 28109402; PMCID: PMC5410376. | spa |
dc.relation.references | 50 Protocolo PETHEMA. Sociedad Española de Hematología y Hemoterapia, SEHH, https://www.sehh.es/servicios-para-los-socios/558-servicios-para-los socios/pethema/protocolos/lam | spa |
dc.relation.references | 51. Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, Ma C, Ma X, Yao Y, Zhou L, Wang Q, Wang L, Zhao Y, Jing Y, Wang L, Li Y, Yu L. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015 Jul 21;10(7):e0132620. doi: 10.1371/journal.pone.0132620. PMID: 26197471; PMCID: PMC4510363 | spa |
dc.contributor.cvlac | Sossa Melo, Claudia Lucía [0001425704] | spa |
dc.contributor.cvlac | Ochoa Vera, Miguel Enrique [0000898465] | spa |
dc.contributor.googlescholar | Sossa Melo, Claudia Lucía [es&oi=ao] | spa |
dc.contributor.orcid | Sossa Melo, Claudia Lucía [0000-0001-9876-222X] | spa |
dc.contributor.orcid | Ochoa Vera, Miguel Enrique [0000-0002-4552-3388] | spa |
dc.contributor.researchgate | Sossa Melo, Claudia Lucía [Claudia-Sossa] | spa |
dc.contributor.researchgate | Ochoa Vera, Miguel Enrique [Miguel-Ochoa-6] | spa |
dc.subject.lemb | Medicina interna | spa |
dc.subject.lemb | Medicina | spa |
dc.subject.lemb | Ciencias médicas | spa |
dc.subject.lemb | Neoplasia | spa |
dc.subject.lemb | Condiciones precancerossas | spa |
dc.subject.lemb | Leucemia mieloide aguda | spa |
dc.subject.lemb | Anormalidades genéticas | spa |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | spa |
dc.description.abstractenglish | Introduction: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an overall 5-year survival of 27.7%, however compared to previous periods this has improved thanks to a better understanding of the different prognostic factors that include those related to the patient and the disease, but their impact on the clinical results of patients with AML at the FOSCAL clinic are not known. Objective: To identify prognostic association factors regarding overall survival and event-free survival in the cohort of patients with acute myeloid leukemia from the FOSCAL clinic, in the period from January 1, 2009 to June 30, 2021. Materials and methods: sociodemographic information and clinical characteristics of patients with AML treated at FOSCAL were retrospectively recorded. The characteristics of the patients at diagnosis are described; Kaplan Meier analysis was used to assess overall survival and event-free survival. The hazzard ratio and 95% confidence intervals crude and adjusted for covariates were also calculated. | spa |
dc.subject.proposal | Ciencias de la salud | spa |
dc.subject.proposal | Cáncer | spa |
dc.subject.proposal | Leucemias | spa |
dc.subject.proposal | Enfermedad residual medible | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/TM | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
dc.coverage.campus | UNAB Campus Bucaramanga | spa |
dc.description.learningmodality | Modalidad Presencial | spa |